FY ending March 2027 second-quarter (first-half) results overview | Bando Chemical Industries,Ltd. (5195) timely disclosure

Worth reading

68In focus

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Improvement

Direction inferred from the company’s description.

Scale

5663

Millions of yen (year-on-year increase in revenue)

Wording

Conditional

How definitive the wording is.

Contents of this document

Earnings presentation materialsSecond quarter (interim period) of the fiscal year ending March 202710 items taken from the company’s own explanation

Financial Results Figures (The key points of this material are explained below)

Net Sales64,757 Millions of yen+9.6%

Operating profit6,774 Millions of yen

Net income5,134 Millions of yen

Results for the three months of the current quarter

Revenue

¥325 100 million

Core operating profit

¥20 100 million

Full-year earnings forecast

Revenue

125,000 Millions of yen

Core operating profit

10,000 Millions of yen

Operating profit

11,500 Millions of yen

Profit for the period attributable to owners of the parent

8,200 Millions of yen

Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。

Revenue51.8%

Core operating profit59.4%

Operating profit58.9%

Interim profit attributable to owners of the parent62.6%

What the company explained in this material

Self-assessment against the planThe company's self-assessment against its own plan.

Tracking above the initial plan

Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.

Core operating profit

Higher gross profit resulting from changes in revenue768

Change in the cost-of-sales ratio948

Foreign-exchange effect (gross profit)849

Increase in SG&A expenses-659

Foreign-exchange effect (SG&A)-431

Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.

USD

155 Yen

THB

4.7 Yen

Renminbi

23 Yen

New initiatives

Investment in Pyrenee Co., Ltd. in May 2026
Expansion of sales of the absorbable bone-regeneration material “e=Bone®” in the medical device and healthcare equipment business
Business expansion into the global aftermarket and personal mobility fields
Continued launch of new products to address customer challenges

Key KPIsA metric the company considers important as a management benchmark.

ROE12.1 %
PBR0.89 Times
Number of one-on-one meetings with investors20 Meetings FY2025 actual
CO2 Emissions Reduction Targets38 % vs. FY2013

Segment results

Automotive Parts Business

Revenue

33,065 Millions of yen+12.2%

Core operating profit

3,225 Millions of yen+32.6%

Industrial Materials Business

Revenue

20,606 Millions of yen+4.4%

Core operating profit

1,954 Millions of yen+16.9%

High-performance elastomer products business

Revenue

7,996 Millions of yen+12.3%

Core operating profit

459 Millions of yen+226.6%

Other

Revenue

3,789 Millions of yen+20.2%

Core operating profit

322 Millions of yen+293.8%

Medium-term management plan targets

Revenue

¥1,200 100 million

Core operating profit

¥120 100 million

ROE

12 %

CO2 Emissions Reduction

38 % vs. FY2013

Target fiscal yearCV-1 / FY2026

Financial targets

ROE

Target12% (through the fiscal year ending March 2027)

Actual results12.1% (fiscal year ending March 2026)

PBR

Actual resultsAt the 1x level

Annual Dividend

¥102 per share

End of period52

Acquisition of treasury shares

Number of shares acquired1.3 million shares (maximum)

Acquisition price¥2 billion (maximum)

Period15 May 2026–30 April 2027

Contents of this document
Item	Details
Document type	Earnings presentation materials
Fiscal Period Covered	Second quarter (interim period) of the fiscal year ending March 2027
Net Sales	64,757 Millions of yen (YoY +9.6%)
Operating profit	6,774 Millions of yen
Net income	5,134 Millions of yen
Results for the three months of the current quarter	Revenue ¥325 100 million / Core operating profit ¥20 100 million
Full-year earnings forecast	Revenue 125,000 Millions of yen / Core operating profit 10,000 Millions of yen / Operating profit 11,500 Millions of yen / Profit for the period attributable to owners of the parent 8,200 Millions of yen
Progress against full-year forecast	Revenue 51.8% / Core operating profit 59.4% / Operating profit 58.9% / Interim profit attributable to owners of the parent 62.6%
Self-assessment against the plan	Tracking above the initial plan
Segment results	Automotive Parts Business Revenue 33,065 Millions of yen (YoY +12.2%) / Core operating profit 3,225 Millions of yen (YoY +32.6%) / Industrial Materials Business Revenue 20,606 Millions of yen (YoY +4.4%) / Core operating profit 1,954 Millions of yen (YoY +16.9%) / High-performance elastomer products business Revenue 7,996 Millions of yen (YoY +12.3%) / Core operating profit 459 Millions of yen (YoY +226.6%) / Other Revenue 3,789 Millions of yen (YoY +20.2%) / Core operating profit 322 Millions of yen (YoY +293.8%)
Breakdown of Factors Affecting the Change	Core operating profit Higher gross profit resulting from changes in revenue 768 / Change in the cost-of-sales ratio 948 / Foreign-exchange effect (gross profit) 849 / Increase in SG&A expenses -659 / Foreign-exchange effect (SG&A) -431
Key KPIs	Indicator name ROE / Value 12.1 % / Year on year against the same period last year Not disclosed, Indicator name PBR / Value 0.89 Times / Year on year against the same period last year Not disclosed, Indicator name Number of one-on-one meetings with investors / Value 20 Meetings (FY2025 actual) / Year on year against the same period last year Not disclosed, Indicator name CO2 Emissions Reduction Targets / Value 38 % (vs. FY2013) / Year on year against the same period last year Not disclosed
Assumptions Underlying the Business Outlook	USD 155 Yen / THB 4.7 Yen / Renminbi 23 Yen
Medium-term management plan targets	Revenue ¥1,200 100 million / Core operating profit ¥120 100 million / ROE 12 % / CO2 Emissions Reduction 38 % (vs. FY2013) / Target fiscal year CV-1 / FY2026
Financial targets	ROE Target 12% (through the fiscal year ending March 2027) / Actual results 12.1% (fiscal year ending March 2026) / PBR Actual results At the 1x level
Annual Dividend	¥102 per share
Acquisition of treasury shares	Number of shares acquired 1.3 million shares (maximum) / Acquisition price ¥2 billion (maximum) / Period 15 May 2026–30 April 2027
New initiatives	Investment in Pyrenee Co., Ltd. in May 2026, Expansion of sales of the absorbable bone-regeneration material “e=Bone®” in the medical device and healthcare equipment business, Business expansion into the global aftermarket and personal mobility fields, Continued launch of new products to address customer challenges

Items this document does not state (13)

Ordinary incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookPayout ratioCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Solid domestic and overseas sales, the impact of the weaker yen, and improved profitability resulting from higher revenue and changes in the product mix, among other factors. The full-year forecast was revised because the assumed exchange rate was reviewed in light of current foreign exchange rates.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.